These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23328324)

  • 1. Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.
    Nomura M; Inoue K; Matsushita S; Takahari D; Kondoh C; Shitara K; Ura T; Hayashi K; Kojima H; Kamata M; Tatematsu M; Hosoda R; Sawada S; Oka H; Muro K
    Clin J Pain; 2013 Jun; 29(6):487-91. PubMed ID: 23328324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal fentanyl in cachectic cancer patients.
    Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
    Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.
    Samala RV; Bloise R; Davis MP
    J Pain Symptom Manage; 2014 Jul; 48(1):132-6. PubMed ID: 24291296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
    Kornick CA; Santiago-Palma J; Khojainova N; Primavera LH; Payne R; Manfredi PL
    Cancer; 2001 Dec; 92(12):3056-61. PubMed ID: 11753984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
    Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL
    Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
    Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
    Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of transdermally administered fentanyl in dogs.
    Kyles AE; Papich M; Hardie EM
    Am J Vet Res; 1996 May; 57(5):715-9. PubMed ID: 8723888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
    Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.
    Carroll GL; Hooper RN; Boothe DM; Hartsfield SM; Randoll LA
    Am J Vet Res; 1999 Aug; 60(8):986-91. PubMed ID: 10451210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
    Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G
    Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain.
    Reinhart DJ; Goldberg ME; Roth JV; Dua R; Nevo I; Klein KW; Torjman M; Vekeman D
    Can J Anaesth; 1997 Apr; 44(4):377-84. PubMed ID: 9104519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
    Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H
    Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
    Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
    Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.